Ralaniten acetate - ESSA Pharma

Drug Profile

Ralaniten acetate - ESSA Pharma

Alternative Names: EPI 506

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ESSA Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 01 Dec 2017 ESSA Pharmaceuticals terminates a phase I/II trial in Prostate cancer (Hormone refractory, Second-line therapy or greater) in United Kingdom, USA, Canada due to excessive high pill burden at the end of phase I (PO) (NCT02606123)
  • 11 Sep 2017 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Canada and USA (PO)
  • 09 Sep 2017 Updated efficacy and safety data from a phase I/II trial in Prostate cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top